Language selection


Summary Basis of Decision - - Health Canada

Summary Basis of Decision (SBD) for


Submission control no:

Date issued:


Health Canada's Summary Basis of Decision (SBD) documents outline the scientific and regulatory considerations that factor into Health Canada regulatory decisions related to drugs and medical devices. SBDs are written in technical language for stakeholders interested in product-specific Health Canada decisions, and are a direct reflection of observations detailed within the evaluation reports. As such, SBDs are intended to complement and not duplicate information provided within the Product Monograph.

Readers are encouraged to consult the 'Reader's Guide to the Summary Basis of Decision - Drugs' to assist with interpretation of terms and acronyms referred to herein. In addition, a brief overview of the drug submission review process is provided in the Fact Sheet entitled 'How Drugs are Reviewed in Canada'. This Fact Sheet describes the factors considered by Health Canada during the review and authorization process of a drug submission. Readers should also consult the 'Summary Basis of Decision Initiative - Frequently Asked Questions' document.

The SBD reflects the information available to Health Canada regulators at the time a decision has been rendered. Subsequent submissions reviewed for additional uses will not be captured under Phase I of the SBD implementation strategy. For up-to-date information on a particular product, readers should refer to the most recent Product Monograph for a product. Health Canada provides information related to post-market warnings or advisories as a result of adverse events (AE).

For further information on a particular product, readers may also access websites of other regulatory jurisdictions. The information received in support of a Canadian drug submission may not be identical to that received by other jurisdictions.

Other Policies and Guidance

Readers should consult the Health Canada website for other drug policies and guidance documents. In particular, readers may wish to refer to the 'Management of Drug Submissions Guidance'.

1 Product and submission information

Brand name:


Medicinal ingredient:

International non-proprietary Name:


Dosage form:

Route of administration:

Drug identification number(DIN):

Therapeutic Classification:

Non-medicinal ingredients:

Submission type and control no:

Date of Submission:

Date of authorization:

2 Notice of decision

3 Scientific and Regulatory Basis for Decision

3.1 Quality Basis for Decision

3.2 Non-clinical Basis for Decision

3.3 Clinical Basis for Decision

3.4 Benefit/Risk Assessment and Recommendation

4 Submission Milestones

Submission Milestones: 

Submission milestone Date
Date modified: